Search For
7 result(s) for 'PARP inhibitors'
The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities
Open Access Review 27 Jul 2023
DOI: 10.20517/cdr.2023.08
Teresa Zielli, ... Ilaria Colombo
Views: Downloads:
Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
Open Access Opinion 31 May 2022
Views: Downloads:
Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
Open Access Review 11 May 2022
DOI: 10.20517/cdr.2022.13
Michael J. Flynn, Jonathan A. Ledermann
Views: Downloads:
Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective
Open Access Perspective 11 May 2022
DOI: 10.20517/cdr.2022.01
Views: Downloads:
Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?
Open Access Commentary 9 Jul 2020
DOI: 10.20517/cdr.2020.27
Views: Downloads:
Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology
Open Access Review 18 Sep 2019
DOI: 10.20517/cdr.2019.50
Views: Downloads:
PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues
Open Access Review 18 Sep 2019
Pooja Murthy, Franco Muggia
, Franco Muggia
Views: Downloads:
- 1
